Opus Genetics, Inc.

IRD Nasdaq CIK: 0001228627

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 8 DAVIS DRIVE, DURHAM, NC, 27713
Mailing Address 8 DAVIS DRIVE, DURHAM, NC, 27713
Phone 248-681-9815
Fiscal Year End 1231
EIN 113516358

Financial Overview

FY2025

-$49.59M
Net Income
$50.24M
Total Assets
$49.91M
Stockholders' Equity
$45.09M
Cash & Equivalents
$-0.80
EPS

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement March 23, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
S-3 Shelf registration for future offerings March 13, 2026 View on SEC
10-K Annual financial report March 12, 2026 View on SEC
8-K Current report of material events March 10, 2026 View on SEC
8-K Current report of material events February 19, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC

Annual Reports

10-K March 12, 2026
  • Successfully completed patient enrollment for its lead gene therapy program, IRD-101, with initial efficacy signals anticipated in mid-2026.
  • Raised significant capital of $42.5 million in 2025 through private placements, registered direct offerings, and an At-The-Market (ATM) program.
View Analysis

Insider Trading

STRONG SELL 6 insiders 7 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.